Biomarkers for neurodegeneration impact cognitive function: a longitudinal 1-year case-control study of patients with bipolar disorder and healthy control individuals.

"Declarations Ethics approval and consent to participateThe study was approved by the Local Ethical Committee (H-6-2014-006) and the Danish Data Protection Agency, Capital Region of Copenhagen. The study complied with the latest Declaration of Helsinki. Competing interestsAuthors UK, AHS, MW, JF, and SGH declare no conflicts of interest. HZ has served on scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, and Biogen. KB has served as a consultant or on advisory boards for Alzheon, BioArtic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Pfizer, and Roche Diagnostics. HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg. KWM reports having received consultancy fees from Lundbeck and Janssen in the past 3 years. LVK has within the preceding 3 years been a consultant for Lundbeck and Teva. Competing interests Authors UK, AHS, MW, JF, and SGH declare no conflicts of interest. HZ has served on scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, and Biogen. KB has served as a consultant or on advisory boards for Alzheon, BioArtic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Pfizer, and Roche Diagnostics. HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg. KWM reports having received consultancy fees from Lundbeck and Janssen in the past 3 years. LVK has within the preceding 3 years been a consultant for Lundbeck and Teva."

"Funding Open access funding provided by Copenhagen University. UK is appointed as an associated professor at the University of Copenhagen and Mental Health Services—Capital Region of Denmark. AHS is funded by Absalonfonden. KWM has received consultancy fees from Lundbeck and Janssen-Cilag in the past 3 years. KWM, SGH, and LVK are appointed as professors at the University of Copenhagen and Mental Health Services—Capital Region of Denmark. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. KB holds the Torsten Söderberg Professorship in medicine and receives funding from the Swedish Research Council and the ALFGBG."